Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Multiple Sclerosis

Journal Scan / Research · November 30, 2024

Infection Risk Associated With High-Efficacy Disease-Modifying Therapies for MS

Clinical Pharmacology and Therapeutics

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Pharmacology and Therapeutics
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
Clin Pharmacol Ther 2024 Nov 15;[EPub Ahead of Print], J Li, GJ Hutton, TJ Varisco, Y Lin, EJ Essien, RR Aparasu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading